Penetrating keratoplasty and glaucoma.
Glaucoma remains the leading cause of blindness after penetrating keratoplasty. Post-keratoplasty glaucoma was originally described in 1969, and its management is still controversial. Recent developments in management include newer classes of drugs, surgical procedures, such as trabeculectomy with mitomycin-C, implantation of glaucoma drainage devices, and cyclodestructive procedures with Nd: YAG and diode lasers. However, the risk of graft failure continues to be high with all surgical procedures.
Ayyala
R S
RS
Glaucoma Service, Department of Ophthalmology, Tulane University Medical Center, New Orleans, LA, USA.
D000477:Alkylating Agents / Q000008:administration & dosage; D003937:Diagnosis, Differential; D005901:Glaucoma / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D020327:Glaucoma Drainage Implants; D006801:Humans; D015994:Incidence; D007429:Intraocular Pressure / Q000502:physiology; D015948:Keratoplasty, Penetrating / Q000009:adverse effects*; D016685:Mitomycin / Q000008:administration & dosage; D009883:Ophthalmic Solutions; D011379:Prognosis; D054140:Refractive Surgical Procedures; D012307:Risk Factors; D014130:Trabeculectomy
D000477:Alkylating Agents; D009883:Ophthalmic Solutions; D016685:Mitomycin